Quantinno Capital Management LP lowered its stake in Biogen Inc. (NASDAQ:BIIB – Free Report) by 62.8% during the third ...

Fintel reports that on December 9, 2024, Jefferies downgraded their outlook for Biogen (NasdaqGS:BIIB) from Buy to Hold.

It is hard to get excited after looking at Biogen's (NASDAQ:BIIB) recent performance, when its stock has declined ...

Integrated Wealth Concepts LLC reduced its position in Biogen Inc. (NASDAQ:BIIB – Free Report) by 61.3% during the third ...

Biogen (BIIB) was downgraded to hold by Jefferies over an anticipated royalty cut for Ocrevus, lackluster pipeline, and expected modest sales of Leqembi. Read more here.

GET MORE AI-GENERATED SIGNALS: November 30, 2024, 22:30 pm ET, BY Rick O.- Contributor| Editor: Thomas H. Kee Jr. ( Follow on ...

In trading on Tuesday, shares of Biogen Inc (Symbol: BIIB) entered into oversold territory, hitting an RSI reading of 29.9, after changing hands as low as $154.99 per share. By comparison ...

Jefferies downgraded Biogen Inc (NASDAQ:BIIB), citing the company’s tough setup. Leqembi (lecanemab) sales growth remains ...

Though there is uncertainty about Biogen's sales and profits improving significantly, investors can hold the stock given the potential of its new drugs.

The market seems to share this rosy outlook, since Biogen has a short interest of only 2.1%. This represents the percentage ...

The Centers for Medicare & Medicaid Services has directed private insurers providing Medicare Advantage plans to cover Biogen ...

Shares of Biogen Inc. BIIB shed 3.41% to $150.03 Friday, on what proved to be an all-around mixed trading session for the ...